New Amsterdam Pharma Funding: $196M Raised, Series A (2020)
New Amsterdam Pharma has raised $196M in total funding. Latest round: Series A. Backed by Forbion, Morningside Ventures, Ascendant BioCapital.
New Amsterdam Pharma funding overview
New Amsterdam Pharma has raised $196M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series A announced in August 2020. The round record for New Amsterdam Pharma runs through 2020; nothing later has been disclosed. Investors on record include Forbion, Morningside Ventures, Ascendant BioCapital, Kaiser Foundation Hospitals, BVF Partners L.P., Population Health Partners and 8 others. 14 distinct backers are named across the disclosed rounds.
New Amsterdam Pharma at a glance
Total raised
$196M
Latest round
Series A
Latest round date
August 2020
Notable investors
Forbion, Morningside Ventures, Ascendant BioCapital, Kaiser Foundation Hospitals, BVF Partners L.P., Population Health Partners, LSP Dementia Fund, Peter Thiel
Frequently asked about New Amsterdam Pharma funding
How much has New Amsterdam Pharma raised?
New Amsterdam Pharma has raised $196M in total disclosed funding across the rounds on record.
Who has invested in New Amsterdam Pharma?
Forbion, Morningside Ventures, Ascendant BioCapital, Kaiser Foundation Hospitals, BVF Partners L.P., Population Health Partners are named among the investors backing New Amsterdam Pharma.
What was the latest New Amsterdam Pharma funding round?
The most recent disclosed round is a Series A, announced in August 2020.
Where is New Amsterdam Pharma based?
No headquarters location is disclosed for New Amsterdam Pharma.
When did New Amsterdam Pharma last raise?
The last disclosed New Amsterdam Pharma round closed in August 2020 at Series A.
Round data for New Amsterdam Pharma is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies and backer lists below.
